Previous 10 | Next 10 |
New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLC Continue to exp...
CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, M...
First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC) Oral presentation featuring the primary analysis from Phase 2 GEMSTONE-2...
EQRx, Inc. (EQRX) Q4 2021 Earnings Conference Call March 23, 2022 8:00 AM ET Company Participants Neil Swami – Head-Investor Relations Melanie Nallicheri – President and Chief Executive Officer Eric Hedrick – Chief Physician Executive Jami Rubin – Chief Financial O...
EQRx press release (NASDAQ:EQRX): FY GAAP EPS of -$0.31. Cash and cash equivalents totaled $1.67B at December 31, 2021. For further details see: EQRx GAAP EPS of -$0.31
First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDA Continue expanding the Global Buyers Club; goal is to have MOUs in place with payers and health systems that c...
Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Wednesday...
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in a fireside chat at ...
Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapy Overall survival benefit demonstrated regardless of tumor pathologic subtype or PD-L1 expression levels C...
News, Short Squeeze, Breakout and More Instantly...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective specia...
NEW YORK, NY / ACCESSWIRE / October 20, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CM Life Sciences III Inc. ("CM Life Sciences"), which was acquired by EQRx, Inc. ("EQRx") (NASDAQ:EQRX) on August 5, 2021. Investors who purchased CM...